PDPHF (Egetis Therapeutics AB) EPS without NRI: $-0.10 (TTM As of Mar. 2026)


PDPHF Egetis Therapeutics AB PDPHF
24 GF Score
Price $0.64
GF Value $0.64
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB EPS without NRI?

Egetis Therapeutics AB PDPHF 24 EPS without NRI is $-0.10 as of Mar. 2026. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,176 Biotechnology companies, Egetis Therapeutics AB ranks worse than 67.69% on this metric.

Egetis Therapeutics AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.10.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 2.90% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Egetis Therapeutics AB's EPS without NRI or its related term are showing as below:

PDPHF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -194.1   Med: -1   Max: 53.6
Current: 2.9

During the past 13 years, Egetis Therapeutics AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 53.60% per year. The lowest was -194.10% per year. And the median was -1.00% per year.

PDPHF's 3-Year EPS without NRI Growth Rate is ranked worse than
67.69% of 1176 companies
in the Biotechnology industry
Industry Median: 16.75 vs PDPHF: 2.90

Egetis Therapeutics AB's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.10.

Egetis Therapeutics AB's EPS (Basic) for the three months ended in Mar. 2026 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.10.


Egetis Therapeutics AB  (OTCPK:PDPHF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Egetis Therapeutics AB EPS without NRI Related Terms


Egetis Therapeutics AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB EPS without NRI Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.10 -0.13 -0.10 -0.10

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.03 -0.02

PDPHF vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's PE Ratio without NRI falls into.


PDPHF
24GF Score
Egetis Therapeutics AB PDPHF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.10 mean?
Egetis Therapeutics AB (PDPHF) has a EPS without NRI of $-0.10 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Egetis Therapeutics AB and its competitors. According to the industry distribution chart, Egetis Therapeutics AB ranks #796 out of 1176 companies in the Biotechnology industry, placing it in the top 67.7%.
Is Egetis Therapeutics AB's EPS without NRI too high?
Egetis Therapeutics AB's current EPS without NRI is $-0.10. Based on the distribution chart, Egetis Therapeutics AB ranks #796 out of 1176 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #796 out of 1176 companies for EPS without NRI. This places Egetis Therapeutics AB in the lower half of its industry. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current EPS without NRI is $-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current EPS without NRI is $-0.10. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current EPS without NRI is $-0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued. The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for PDPHF:

  • EPS without NRI: $-0.10
  • GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score

Get the complete analysis for PDPHF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price
$0.64
GF Value